结肠炎
彭布罗利珠单抗
医学
免疫系统
免疫学
背景(考古学)
结直肠癌
CD8型
T细胞
细胞毒性T细胞
癌症
癌症研究
免疫疗法
内科学
生物
体外
古生物学
生物化学
作者
Jacqueline E. Mann,Liliana E. Lucca,Matthew R Austin,Ross D. Merkin,Marie E. Robert,Badr Al‐Bawardy,Khadir Raddassi,Lilach Aizenbud,Nikhil S. Joshi,David A. Hafler,Clara Abraham,Kevan C. Herold,Harriet M. Kluger
标识
DOI:10.1136/jitc-2023-007358
摘要
Immune checkpoint inhibitors (ICIs) are increasingly being used to manage multiple tumor types. Unfortunately, immune-related adverse events affect up to 60% of recipients, often leading to treatment discontinuation in settings where few alternative cancer therapies may be available. Checkpoint inhibitor induced colitis (ICI-colitis) is a common toxicity for which the underlying mechanisms are poorly defined. To better understand the changing colon-specific and peripheral immune environments over the course of progression and treatment of colitis, we collected blood and colon tissue from a patient with Merkel cell carcinoma who developed colitis on treatment with pembrolizumab. We performed single-cell RNA sequencing and T-cell receptor sequencing on samples collected before, during and after pembrolizumab and after various interventions to mitigate toxicity. We report T-cells populations defined by cytotoxicity, memory, and proliferation markers at various stages of colitis. We show preferential depletion of CD8+ T cells with biologic therapy and nominate both circulating and colon-resident T-cell subsets as potential drivers of inflammation and response to immune suppression. Our findings highlight the need for further exploration of the colon immune environment and rationalize future studies evaluating biologics for ICI-colitis, including in the context of ICI re-challenge.
科研通智能强力驱动
Strongly Powered by AbleSci AI